Literature DB >> 19782743

Characterization, stabilization and activity of uricase loaded in lipid vesicles.

Q Y Tan1, N Wang, H Yang, L K Zhang, S Liu, L Chen, J Liu, L Zhang, N N Hu, C J Zhao, J Q Zhang.   

Abstract

Uricase-containing lipid vesicles (UOXLVs) were prepared by reverse-phase evaporation method with high efficiency and the characteristics of UOXLVs were described. The average size and zeta potential of UOXLVs obtained by the optimized formulation were 205.47 nm and -37.33 mV, respectively. Uricase was encapsulated in the alkaline aqueous phase of the lipid vesicle and the stability of its tetrameric structure was thus improved and its activity preserved. The storage stability of uricase in lipid vesicles was significantly increased compared to that of free uricase at 4 degrees C in borate buffer of pH 8.5. At 55 degrees C, free uricase was deactivated much more quickly especially at lower concentration predominantly due to enhanced dissociation of uricase into subunits. An intrinsic tryptophan of uricase recovered from the lipid vesicle thermally treated at 55 degrees C revealed that a partially denatured uricase molecule was stabilized through its hydrophobic interaction with lipid vesicle membrane. This interaction was depressed mainly by dissociation of uricase into subunits. At the physiological pH, significant increase of enzyme activity was found for the uricase entrapped in the lipid vesicles (1.8 times that of free uricase) at their respective optimum pH. The shift of optimum pH and increased uricolytic activity suggested the conformation change of the uricase during the entrapment process. The stability to proteolytic digestion was increased obviously by entrapping the uricase in the lipid vesicles. UOXLVs also showed relatively slower loss in activity compared with free uricase when treated with some chemical reagents. Lastly, in vitro study explicitly indicated that the uricase entrapped by UOXLVs possessed higher uricolytic activity than that of native uricase solution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782743     DOI: 10.1016/j.ijpharm.2009.09.036

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach.

Authors:  Sanjay Tiwari; Harinath Dwivedi; Koshy M Kymonil; Shubhini A Saraf
Journal:  Drug Deliv Transl Res       Date:  2015-06       Impact factor: 4.617

2.  Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability.

Authors:  Qunyou Tan; Shan Liu; Xueliang Chen; Mingjun Wu; Hong Wang; Huafeng Yin; Dan He; Huarong Xiong; Jingqing Zhang
Journal:  AAPS PharmSciTech       Date:  2012-03-28       Impact factor: 3.246

3.  Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.

Authors:  Qun-You Tan; Jing-Qing Zhang; Na Wang; Hong Yang; Xiaoling Li; Hua-Rong Xiong; Jian-Yong Wu; Chun-Jing Zhao; Hong Wang; Hua-Feng Yin
Journal:  Int J Nanomedicine       Date:  2012-07-23

4.  Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics.

Authors:  Qunyou Tan; Rong Jiang; Meiling Xu; Guodong Liu; Songlin Li; Jingqing Zhang
Journal:  Int J Nanomedicine       Date:  2013-02-20

5.  Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes.

Authors:  Yunli Zhou; Mi Zhang; Dan He; Xueyuan Hu; Huarong Xiong; Jianyong Wu; Biyue Zhu; Jingqing Zhang
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.